Home/Pipeline/Claudin 18.2 ADC (CSPC-5902)

Claudin 18.2 ADC (CSPC-5902)

Advanced solid tumors

Phase IActive

Key Facts

Indication

Advanced solid tumors

Phase

Phase I

Status

Active

Company

CSPC Pharmaceutical Group Limited

About CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group's mission is to deliver high-quality, accessible pharmaceutical products while advancing innovative therapeutics through sustained R&D investment. The company has achieved a dominant position in China's nervous system and cardiovascular markets, established itself as a global API supplier, and is now transitioning toward a more innovation-driven future with several novel drug candidates in late-stage development. Its strategy hinges on leveraging its integrated manufacturing and distribution strengths to maximize the lifecycle of its established products while systematically commercializing its innovative pipeline to capture higher-margin opportunities.

View full company profile

Therapeutic Areas

Oncology Nervous System Cardiovascular & Metabolic Anti-infectives Autoimmune/Inflammatory

Other Advanced solid tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BP1001-A	Bio-Path Holdings	Phase 1	Active
FS222	F-star Therapeutics	Phase 1	Active (status post-acquisition)
FS120	F-star Therapeutics	Phase 1	Active (status post-acquisition)
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active